Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates
Merck shares rose 2.2% in after-hours trading Tuesday, closing at $115.84 after the company’s 2026 revenue forecast missed Wall Street estimates. The drugmaker cited a $2.5 billion hit from patent expirations, Medicare price talks, and weaker COVID-19 pill sales. Investors are watching Keytruda demand, Gardasil’s China performance, and FDA decisions expected later in 2026.